AGC (5201) investor relations material

Executive summary

• FY2025 net sales were flat at ¥2,058.8 billion, with operating profit rising to ¥127.5 billion, driven by Automotive improvements and cost measures.

• Profit attributable to owners of parent improved to ¥69.2 billion, with ROE rising to 4.7%.

• Major impairments in Display (2022) and Biopharmaceutical CDMO (2024) previously weighed on results, but initiatives have stabilized earnings.

• Profit before tax rebounded to ¥124.8 billion from a prior-year loss, mainly due to the absence of one-time losses.

• FY2025 saw a moderate global economic recovery, with regional differences: US growth supported by investment, China and Europe lagging, and Japan showing moderate recovery.

Financial highlights

• Net sales decreased by ¥8.8 billion year-over-year; operating profit rose by ¥1.6 billion to ¥127.5 billion.

• Profit before tax surged by ¥174.8 billion, reflecting the absence of prior-year losses from Russian business transfer and large impairments.

• Free cash flow was ¥96.1 billion, up from ¥89.2 billion in the prior year.

• CapEx was ¥251.3 billion, depreciation ¥179.8 billion, and R&D expenses ¥60.3 billion.

• Basic earnings per share reached ¥326.20, up from a loss per share of ¥443.71 in FY2024.

Outlook and guidance

• FY2026 forecasts net sales of ¥2,200 billion (+6.9%), operating profit of ¥150 billion (+17.7%), and ROE of 5.2%.

• Profit attributable to owners is projected at ¥77.0 billion, and EPS at ¥363.12.

• Life Science segment expected to drive profit improvement; CapEx to decrease as major expansions conclude.

• Dividend forecast for FY2026 is maintained at ¥210 per share.

• Commitment to achieve operating profit target, with downside risks already factored in.